CA2520197A1 - Sachet for a pharmaceutical composition - Google Patents

Sachet for a pharmaceutical composition Download PDF

Info

Publication number
CA2520197A1
CA2520197A1 CA002520197A CA2520197A CA2520197A1 CA 2520197 A1 CA2520197 A1 CA 2520197A1 CA 002520197 A CA002520197 A CA 002520197A CA 2520197 A CA2520197 A CA 2520197A CA 2520197 A1 CA2520197 A1 CA 2520197A1
Authority
CA
Canada
Prior art keywords
sachet
m2
sachet according
preferably
per unit
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002520197A
Other languages
French (fr)
Inventor
Carin Widerstrom
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ferring BV
Original Assignee
Ferring B.V.
Carin Widerstrom
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
Priority to DKPA200300612 priority Critical
Priority to US46464903P priority
Priority to EP03388023.8 priority
Priority to US60/464,649 priority
Priority to EP20030388023 priority patent/EP1470819A1/en
Priority to DKPA200300612 priority
Application filed by Ferring B.V., Carin Widerstrom filed Critical Ferring B.V.
Priority to PCT/EP2004/004280 priority patent/WO2004093883A2/en
Publication of CA2520197A1 publication Critical patent/CA2520197A1/en
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36655488&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2520197(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application status is Abandoned legal-status Critical

Links

Classifications

    • BPERFORMING OPERATIONS; TRANSPORTING
    • B32LAYERED PRODUCTS
    • B32BLAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
    • B32B15/00Layered products comprising a layer of metal
    • B32B15/04Layered products comprising a layer of metal comprising metal as the main or only constituent of a layer, which is next to another layer of the same or of a different material
    • B32B15/12Layered products comprising a layer of metal comprising metal as the main or only constituent of a layer, which is next to another layer of the same or of a different material of paper or cardboard
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/60Salicylic acid; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/60Salicylic acid; Derivatives thereof
    • A61K31/606Salicylic acid; Derivatives thereof having amino groups
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1635Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682Processes
    • A61K9/1694Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5036Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5036Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B32LAYERED PRODUCTS
    • B32BLAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
    • B32B15/00Layered products comprising a layer of metal
    • B32B15/04Layered products comprising a layer of metal comprising metal as the main or only constituent of a layer, which is next to another layer of the same or of a different material
    • B32B15/08Layered products comprising a layer of metal comprising metal as the main or only constituent of a layer, which is next to another layer of the same or of a different material of synthetic resin
    • B32B15/085Layered products comprising a layer of metal comprising metal as the main or only constituent of a layer, which is next to another layer of the same or of a different material of synthetic resin comprising polyolefins
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B32LAYERED PRODUCTS
    • B32BLAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
    • B32B15/00Layered products comprising a layer of metal
    • B32B15/20Layered products comprising a layer of metal comprising aluminium or copper
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B32LAYERED PRODUCTS
    • B32BLAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
    • B32B27/00Layered products comprising a layer of synthetic resin
    • B32B27/06Layered products comprising a layer of synthetic resin as the main or only constituent of a layer, which is next to another layer of the same or of a different material
    • B32B27/10Layered products comprising a layer of synthetic resin as the main or only constituent of a layer, which is next to another layer of the same or of a different material of paper or cardboard
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B32LAYERED PRODUCTS
    • B32BLAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
    • B32B27/00Layered products comprising a layer of synthetic resin
    • B32B27/32Layered products comprising a layer of synthetic resin comprising polyolefins
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B32LAYERED PRODUCTS
    • B32BLAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
    • B32B7/00Layered products characterised by the relation between layers; Layered products characterised by the relative orientation of features between layers, or by the relative values of a measurable parameter between layers, i.e. products comprising layers having different physical, chemical or physicochemical properties; Layered products characterised by the interconnection of layers
    • B32B7/04Interconnection of layers
    • B32B7/12Interconnection of layers using interposed adhesives or interposed materials with bonding properties
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B32LAYERED PRODUCTS
    • B32BLAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
    • B32B2307/00Properties of the layers or laminate
    • B32B2307/20Properties of the layers or laminate having particular electrical or magnetic properties, e.g. piezoelectric
    • B32B2307/21Anti-static
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B32LAYERED PRODUCTS
    • B32BLAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
    • B32B2307/00Properties of the layers or laminate
    • B32B2307/70Other properties
    • B32B2307/72Density
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B32LAYERED PRODUCTS
    • B32BLAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
    • B32B2307/00Properties of the layers or laminate
    • B32B2307/70Other properties
    • B32B2307/724Permeability to gases, adsorption
    • B32B2307/7242Non-permeable
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B32LAYERED PRODUCTS
    • B32BLAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
    • B32B2307/00Properties of the layers or laminate
    • B32B2307/70Other properties
    • B32B2307/724Permeability to gases, adsorption
    • B32B2307/7242Non-permeable
    • B32B2307/7246Water vapor barrier
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B32LAYERED PRODUCTS
    • B32BLAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
    • B32B2307/00Properties of the layers or laminate
    • B32B2307/70Other properties
    • B32B2307/726Permeability to liquids, absorption
    • B32B2307/7265Non-permeable
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B32LAYERED PRODUCTS
    • B32BLAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
    • B32B2323/00Polyalkenes
    • B32B2323/04Polyethylene
    • B32B2323/046LDPE, i.e. low density polyethylene
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B32LAYERED PRODUCTS
    • B32BLAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
    • B32B2439/00Containers; Receptacles
    • B32B2439/40Closed containers
    • B32B2439/46Bags
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B32LAYERED PRODUCTS
    • B32BLAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
    • B32B2439/00Containers; Receptacles
    • B32B2439/80Medical packaging
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00Stock material or miscellaneous articles
    • Y10T428/13Hollow or container type article [e.g., tube, vase, etc.]
    • Y10T428/1303Paper containing [e.g., paperboard, cardboard, fiberboard, etc.]

Abstract

The present invention is directed to a sachet for a pharmaceutical composition, comprising the layers: paper; bonding layer; barrier layer; and sealing layer.

Description

SACHET FOR A PHARMACEUTICAL COMPOSITION
Field of the Invention The present invention concerns a sachet for a pharmaceutical composition.
The present writ claims priority from the Danish patent application PA 2003 00612, The European patent application EP 03388023, and the US provisional patent application 60/464649.
Technical Background Oral pharmaceutical formulations comprising mesalazine are known, which are either tablets or granulate.
Granulate may be packed in sachets. For the purposes of the present invention a "sachet" will refer to an envelope or bag for a granulate, while "granulate" refers to particles, granulate or spheronised particles.
Known sachets tend to suffer from the draw back of complicated manufacturing methods or high production costs. In order to being accepted by consumers, a sachet should preferably be easy to open without the use of scissors. Upon pouring granulate from a sachet preferably as little material as possible should be lost. Static electricity may build up between certain granulate types and sachets. This is dependent of the type of granulate as well as the type of sachet. If static electricity is present, it tends to be difficult to pour granulate from the sachet. Finally, granulate in a sachet may be sensitive to degradation by light, humidity and/or air.
This is also dependent of the type of sachet as well as the type of granulate.
Disclosure of the Invention These problems and others mentioned below are addressed by aspects of the invention.
CONFIRMATION COPY

For the purposes of the present invention the term "mesalazine" also encompasses pharmaceutically acceptable salts and esters thereof, such as those mentioned in WO
97/23199 p. 15, 1. 17 - p. 6, 1. 12, as well as prodrugs, such as balsalazide.
The formulation, to be stored in a sachet according to the invention, is preferably in the form of a particulate material, e.g. granulate, spheres, pellets, particles, preferably granulate.
The present sachet may be used for any pharmaceutical formulation, but is especially suitable for storing pharmaceuticals comprising sensitive compounds such as mesalazine.
According to an aspect, the present invention concerns a sachet, comprising the layers:
i) paper;
ii) bonding layer, preferably an adhesive such as polyethylene;
iii) barrier layer, preferably aluminium foil; and iv) sealing layer, preferably low density polyethylene.
Mesalazine is sensitive to humidity, atmospheric air and/or light. A sachet for a product containing mesalazine should therefore preferably provide a barrier to humidity, atmospheric air and light. The sachet should also be easy to open for a patient, preferably without the use of additional tools, such as scissors. It has been a problem to provide a sachet with the necessary barrier properties without sacrificing the possibility of tearing open the sachet with human fingers. Further, existing sachets tend to suffer from the build up of static electricity. Preferably, a sachet should be easy to manufacture, easy to fill, easy to empty, and have an appealing look to improve patient compliance.
This aspect provides a sachet giving long storage stability for a pharmaceutical composition contained therein, e.g. where the active pharmaceutical ingredient is mesalazine. Further, the sachet is easy to tear and static electricity is eliminated, providing for a sachet which may be emptied completely for its contents. The combination of the sachet and the oral formulation according to the present invention provides for little build up of static electricity.
The outer paper i) has in a preferred embodiment a weight per unit area of 10-100 g/m2, preferably 30-70 g/m2, more preferred 40-60 g/m2, most preferred 50 g/m2.
Paper having a weight per unit area outside the range of 10-100 g/mz are hardly suitable in industrial manufacturing of sachets. Paper having a weight per unit area below about 30-40 g/cm2 tend to break in manufacturing equipement for sachets. For paper having a weight per unit area above about 60-70 g/cm2 it is difficult to shape the material to sachets. Optimal results have been achieved with a weight per unit area above of about 50 g/cm2.
According to an aspect, the bonding layer ii) preferably has a weight per unit area of 6-20 g/mz, preferably 9-18 g/m2, more preferred 12-15 g/m2. If a very thin layer is used, it usually neccesitate the use of expensive special polymers to achieve an appropriate coverage. If a thick layer is applied, it inherently more expensive and hard to avoid an uneven layer.
According to an aspect, the barrier layer iii) preferably has a thickness of 6-30 Vim, more preferred 7-25 ~,m, preferably 9-25 Vim, more preferred 8-20 Vim, preferably 9-15 Vim, more preferred 12 ~,m.
Sachet according to any of the preceding claims, wherein said sealing layer iv) has a thickness of 15-50 Vim. If a very thin layer is applied, it has a tendency not to cover the surface completely. If a very thick layer is applied, it is hard to weld through, and any heating applied may not warm evenly.
According to an aspect, the sealing layer iv) preferably has a weight per unit area of 10-100 g/m2, more preferred 15-75 g/m2, preferably 20-50 g/m2, more preferably 30-40 g/mz, most preferred 35 g/m2.
According to an aspect, the present invention concerns the use of the sachet for a pharmaceutical composition according to the invention.
The sachet has proven suitable for storing the pharmaceutical compositions according to the invention.
According to an aspect, the present invention concerns the use of the sachet for medical purposes.
A sachet according to the present sachet is especially suitable for a pharmaceutical formulation comprising mesalazine or a pharmaceutically acceptable salt thereof.
The present sachet has a remarkably low tendency to build up static electricity. This has formerly especially been a problem with mesalazine granulate. As an example of such a mesalazine product may be mentioned granulate obtainable according to the patent application PCT/DKO1/00677.

According to an aspect of the present invention it is not limited to the use of mesalazine as the active ingredient in granulate in the present sachet, but also relates to other active ingredients, such as the ingredients 5 mentioned in WO 00/44353, p. 12-16.
According to an aspect of the present invention further excipients may be comprised in the composition according to the invention, such as fillers, disintegrants, pH
adjusters, or surfactants. Such excipients are well known from the literature, see e.g. WO 00/44353, p. 16-20, for a number of suitable excipients.
Some excipients are hygroscopic. As an example of such excipient povidone may be mentioned. If an active ingredient is to be formulated with a hygroscopic excipient, the need for a suitable sachet is emphasized.
The present sachet is suitable for being used for pharmaceuticals comprising at least one hygroscopic excipient.
Example The material of a sachet had the following composition:
Paper, claycoated 50 g/m2 Polyethylene, low density 12 g/m2 Aluminium foil 12 ~m Polyethylene, low density 35 g/mz For the present example 12 g/m2 PE corresponds to 13 Vim, and 35 g/mz PE corresponds to 38 Vim. The material had a grammage of 129 g/m2. The permeability to water vapour was <0.05 g/m2, 24 h, 25°C, 75% RH, and to OZ <0.05 ml/m2, 24 h, atm, 23°C, 75% RH.
The sachets were folded around the filling tube of a filling/sealing station, such that the paper was on the outside of the sachet, and then sealed lengthwise, with a low density polyethylene as a sealing layer. After forming the cross seal at the bottom the sachet is filled with granulates, and then sealed again at the top and finally cut.
All citations are incorporated in their entirety by reference.

Claims (16)

1. Sachet for a pharmaceutical composition, comprising the layers:

i) paper;
ii) bonding layer;
iii) barrier layer; and iv) sealing layer.
2. Sachet according to claim 1, wherein said barrier layer is an aluminum foil, said bonding layer is preferably of polyethylene, and said sealing layer is preferably a low density polyethylene.
3. Sachet according to claim 1 or 2, wherein said paper i) has a weight per unit area of 10-100 g/m2.
4. Sachet according to claim 3, wherein said paper i) has a weight per unit area of 30-70 g/m2.
5. Sachet according to claim 4, wherein said paper i) has a weight per unit area of 40-60 g/m2.
6. Sachet according to any of the preceding claims, wherein said bonding layer ii) has a weight per unit area of 6-20 g/m2.
7. Sachet according to claim 6, wherein said bonding layer ii) has a weight per unit area of 9-18 g/m2.
8. Sachet according to claim 7, wherein said bonding layer ii) has a weight per unit area of 12-15 g/m2.
9. Sachet according to any of the preceding claims, wherein said sealing layer iv) has a thickness of 15-50 µm.
10. Sachet according to any of the preceding claims, wherein said sealing layer iv) has a weight per unit area of 10-100 g/m2, more preferred 15-75 g/m2, preferably 20-50 g/m2, more preferably 30-40 g/m2, most preferred 35 g/m2.
11. Sachet according to any of the preceding claims, wherein said barrier layer iii) has a thickness of 6-30 µm, more preferred 7-25 µm, preferably 9-25 µm, more preferred 8-20 µm, preferably 9-15 µm, more preferred 12 µm.
12. Sachet according to any of the preceding claims, containing a pharmaceutical formulation.
13. Sachet according to claim 12, wherein said pharmaceutical formulation comprises mesalazine or a pharmaceutically acceptable salt thereof.
14. Sachet according to claim 12 or 13, said sachet containing an oral pharmaceutical formulation in the form of a granulate comprising more than 55% by weight of mesalazine or a pharmaceutically acceptable salt thereof.
15. Use of sachet according to any of the preceding claims for a pharmaceutical composition.
16. Use of a sachet according to any of the claims 1 - 14 for medical purposes.
CA002520197A 2003-04-23 2004-04-22 Sachet for a pharmaceutical composition Abandoned CA2520197A1 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
US46464903P true 2003-04-23 2003-04-23
EP03388023.8 2003-04-23
US60/464,649 2003-04-23
EP20030388023 EP1470819A1 (en) 2003-04-23 2003-04-23 High drug load mesalazine sachet
DKPA200300612 2003-04-23
DKPA200300612 2003-04-23
PCT/EP2004/004280 WO2004093883A2 (en) 2003-04-23 2004-04-22 Sachet for a pharmaceutical composition

Publications (1)

Publication Number Publication Date
CA2520197A1 true CA2520197A1 (en) 2004-11-04

Family

ID=36655488

Family Applications (2)

Application Number Title Priority Date Filing Date
CA002520197A Abandoned CA2520197A1 (en) 2003-04-23 2004-04-22 Sachet for a pharmaceutical composition
CA2520026A Active CA2520026C (en) 2003-04-23 2004-04-23 High drug load mesalazine sachet

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA2520026A Active CA2520026C (en) 2003-04-23 2004-04-23 High drug load mesalazine sachet

Country Status (19)

Country Link
US (3) US20070042143A1 (en)
EP (3) EP1615619A2 (en)
JP (4) JP2007523664A (en)
KR (1) KR100849966B1 (en)
CN (1) CN1777430B (en)
AU (1) AU2004231316B2 (en)
CA (2) CA2520197A1 (en)
CY (1) CY1115560T1 (en)
DK (1) DK1615648T3 (en)
ES (1) ES2486245T3 (en)
HK (2) HK1083312A1 (en)
IL (1) IL170978A (en)
MX (1) MXPA05011308A (en)
NO (1) NO335375B1 (en)
NZ (1) NZ542591A (en)
PT (1) PT1615648E (en)
RU (2) RU2005131492A (en)
SI (1) SI1615648T1 (en)
WO (2) WO2004093883A2 (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6632429B1 (en) 1999-12-17 2003-10-14 Joan M. Fallon Methods for treating pervasive development disorders
US8030002B2 (en) 2000-11-16 2011-10-04 Curemark Llc Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions
US8282955B2 (en) 2001-10-15 2012-10-09 Ferring B.V. Method for the preparation of a pharmaceutical composition comprising 5-aminosalicylic acid for use in treatment of ulcerative colitis and Crohn's disease
CA2520197A1 (en) 2003-04-23 2004-11-04 Ferring B.V. Sachet for a pharmaceutical composition
US7951436B2 (en) 2006-08-14 2011-05-31 Frito-Lay North America, Inc. Environmentally-friendly multi-layer flexible film having barrier properties
US7943218B2 (en) * 2006-08-14 2011-05-17 Frito-Lay North America, Inc. Environmentally-friendly multi-layer flexible film having barrier properties
US7645801B2 (en) 2007-01-29 2010-01-12 Alaven Pharmaceutical Llc Reduced irritant enema for treatment of inflammatory bowel disease (IBD)
US20090169622A1 (en) * 2007-12-27 2009-07-02 Roxane Laboratories, Inc. Delayed-release oral pharmaceutical composition for treatment of colonic disorders
US8658163B2 (en) 2008-03-13 2014-02-25 Curemark Llc Compositions and use thereof for treating symptoms of preeclampsia
WO2009118761A2 (en) * 2008-03-24 2009-10-01 Bhandari Mohan Harakchand Metallized paper based lidding material for blister packaging & process thereof
US8084025B2 (en) 2008-04-18 2011-12-27 Curemark Llc Method for the treatment of the symptoms of drug and alcohol addiction
US20100092447A1 (en) 2008-10-03 2010-04-15 Fallon Joan M Methods and compositions for the treatment of symptoms of prion diseases
EP2334178A4 (en) 2008-10-03 2012-04-11 Falk Pharma Gmbh Compositions and methods for the treatment of bowel diseases with granulated mesalamine
EP2373693A4 (en) 2009-01-06 2012-04-25 Curelon Llc Compositions and methods for the treatment or the prevention oral infections by e. coli
US9056050B2 (en) * 2009-04-13 2015-06-16 Curemark Llc Enzyme delivery systems and methods of preparation and use
WO2011050135A1 (en) 2009-10-21 2011-04-28 Curemark Llc Methods and compositions for the prevention and treatment of influenza
EP2340812A1 (en) 2009-12-18 2011-07-06 Ferring International Center S.A. Granules for pharmaceutical preparations, methods and apparatus for their production
US20130225539A1 (en) * 2010-09-10 2013-08-29 Pharmazell Gmbh Method for producing crystalline 5-aminosalicylic acid
GB2503852B (en) 2011-04-21 2018-12-12 Curemark Llc Compounds for the treatment of neuropsychiatric disorders
US9040120B2 (en) 2011-08-05 2015-05-26 Frito-Lay North America, Inc. Inorganic nanocoating primed organic film
US9267011B2 (en) 2012-03-20 2016-02-23 Frito-Lay North America, Inc. Composition and method for making a cavitated bio-based film
US9162421B2 (en) 2012-04-25 2015-10-20 Frito-Lay North America, Inc. Film with compostable heat seal layer
MX355373B (en) 2012-06-23 2018-04-17 Frito Lay North America Inc Deposition of ultra-thin inorganic oxide coatings on packaging.
US9090021B2 (en) 2012-08-02 2015-07-28 Frito-Lay North America, Inc. Ultrasonic sealing of packages
US9149980B2 (en) 2012-08-02 2015-10-06 Frito-Lay North America, Inc. Ultrasonic sealing of packages
CN102784154B (en) * 2012-09-01 2013-10-09 朱文军 Mesalazine enteric coated tablet and preparation method thereof
WO2015159302A2 (en) * 2014-04-17 2015-10-22 Athena Drug Delivery Solutions Pvt Ltd. Process for preparation of mesalamine composition and mesalamine composition thereof
WO2015193788A1 (en) * 2014-06-16 2015-12-23 Valpharma International S.P.A. Formulation for oral administration containing mesalazine
EP3162362A1 (en) 2015-10-30 2017-05-03 Dr. Falk Pharma Gmbh Optimized high-dose tablet of mesalazine

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4638131B1 (en) 1966-06-22 1971-11-10
US4085244A (en) * 1976-02-10 1978-04-18 Champion International Corporation Balanced orientated flexible packaging composite
US4360550A (en) * 1979-09-12 1982-11-23 Toyo Kagaku Kabushiki Kaisha Composite packing film and packing bag made of the same
JPS57500432A (en) 1980-03-20 1982-03-11
US4960765A (en) 1980-03-20 1990-10-02 Farmaceutisk Laboratorium Ferring A/S Pharmaceutical composition and method for the treatment of colitis ulcerosa and Crohn's disease by oral administration
JPS6048484B2 (en) 1980-05-20 1985-10-28 Alza Corp
JPS5758631A (en) 1980-09-24 1982-04-08 Toyo Jozo Co Ltd Coating composition
ZA8205384B (en) 1981-07-31 1983-05-25 Tillott J B Ltd Orally administrable pharmaceutical compositions
US4418841A (en) * 1982-11-23 1983-12-06 American Can Company Multiple layer flexible sheet structure
DE3151196A1 (en) 1981-12-23 1983-06-30 Kurt Heinz Prof Dr Bauer A process for the production of readily soluble 5-aminosalicylic acid pharmaceutical preparations
US4629657A (en) * 1982-12-13 1986-12-16 Enron Chemical Company Biaxially oriented polypropylene film construction for special lamination
US4489112A (en) * 1983-03-28 1984-12-18 Ex-Cell-O Corporation Laminated paperboard container with absorption resistance means, and blank for constructing same
SE457505B (en) 1984-01-10 1989-01-09 Lejus Medical Ab Laminate coated oral pharmaceutical composition and its foerfarande foer framstaellning
NL8502178A (en) 1984-08-16 1986-03-17 Sandoz Ag Novel pharmaceutical compositions.
US4693395A (en) * 1984-12-28 1987-09-15 Colgate-Palmolive Company Ethylene propylene copolymer in a substrate and collapsible dispensing container made therefrom
US4702905A (en) * 1985-08-30 1987-10-27 Colgate-Palmolive Company Packaged dental cream
US4705680A (en) * 1986-01-22 1987-11-10 Colgate-Palmolive Company Stable dental cream in polyethylene or polypropylene container
US4720473A (en) 1986-03-10 1988-01-19 Cri International, Inc. Production of improved catalyst-type particles using length and density grading
FR2600893B1 (en) * 1986-07-01 1990-01-12 Sandoz Lab New pharmaceutical compositions containing calcium salts
US5254347A (en) 1988-03-31 1993-10-19 Tanabe Seiyaku Co., Ltd. Controlled release pharmaceutical preparation and method for producing the same
US5194464A (en) * 1988-09-27 1993-03-16 Takeda Chemical Industries, Ltd. Enteric film and preparatoin thereof
US5484605A (en) 1988-11-25 1996-01-16 Henning Berlin Gmbh Chemie-Und Pharmawerk Agent for treating chronically inflammatory intestinal diseases
GB8828349D0 (en) * 1988-12-05 1989-01-05 Du Pont Canada Film laminate with easy to td tear
GB8913889D0 (en) 1989-06-16 1989-08-02 May & Baker Ltd New compositions of matter
IT1246382B (en) 1990-04-17 1994-11-18 Eurand Int Method for targeted and controlled sale of drugs in the intestine and particularly the colon
US5433982A (en) * 1990-11-14 1995-07-18 Dai Nippon Printing Co., Ltd. Composite container having barrier property
US5316772A (en) 1990-12-19 1994-05-31 Solvay & Cie, S.A. (Societe Anonyme) Bilayered oral pharmaceutical composition with pH dependent release
GB2253346A (en) * 1991-02-22 1992-09-09 John Rhodes Delayed release oral dosage forms for treatment of intestinal disorders
GB2256587A (en) 1991-06-11 1992-12-16 American Cyanamid Co Acetazolamide in sustained release form
US5472712A (en) 1991-12-24 1995-12-05 Euroceltique, S.A. Controlled-release formulations coated with aqueous dispersions of ethylcellulose
US5474818A (en) * 1992-05-15 1995-12-12 International Paper Flexible container with nonstick interior
JP2607422B2 (en) * 1992-09-08 1997-05-07 呉羽化学工業株式会社 Sachets of oral adsorbent and a method of manufacturing the same
JPH0827133B2 (en) 1993-07-13 1996-03-21 不二パウダル株式会社 Processing apparatus of the wet powder or granular material
US5482718A (en) 1994-03-23 1996-01-09 Hoffmann-La Roche Inc. Colon-targeted delivery system
JPH0880597A (en) * 1994-07-14 1996-03-26 Kyodo Printing Co Ltd Anti-fungus laminate, and bag, container and formed cup using the same
JPH0826977A (en) 1994-07-19 1996-01-30 Tanabe Seiyaku Co Ltd Elution-controlled type oral preparation
IT1277663B1 (en) * 1995-09-28 1997-11-11 Crinos Industria Farmaco stable mesalazine aqueous suspensions for topical use
US6004581A (en) 1995-12-21 1999-12-21 Farmaceutisk Laboratorium Ferring A/S Modified release oral pharmaceutical composition and method for the treatment of bowel diseases
TR199801158T2 (en) * 1995-12-21 1998-09-21 Farmaceutisk Laboratorium Ferring A/S oral pharmaceutical composition for intestinal diseases.
JP2002511774A (en) 1996-07-28 2002-04-16 バイオセンス・インコーポレイテッド Electromagnetic cardiac biostimulation method
US6245351B1 (en) 1996-03-07 2001-06-12 Takeda Chemical Industries, Ltd. Controlled-release composition
IL118932D0 (en) 1996-07-24 1996-10-31 Dexcel Ltd Controlled release tablets
WO1998026767A2 (en) 1996-12-17 1998-06-25 Poli Industria Chimica S.P.A. Site-specific controlled release dosage formulation for mesalamine
GB9722426D0 (en) 1997-10-23 1997-12-24 Univ London Pharmacy Controlled release formulations
EP0939037A1 (en) * 1998-02-26 1999-09-01 Alusuisse Technology &amp; Management AG Packaging material
EP1079820A1 (en) 1998-05-19 2001-03-07 Centaur Pharmaceuticals, Inc. Benzamide therapeutics for the treatment of inflammatory bowel disease
CA2342227C (en) * 1998-09-03 2009-03-24 Leif Norlander Paper or paperboard laminate and method to produce such a laminate
CO5140079A1 (en) 1998-10-14 2002-03-22 Novartis Ag sustained release pharmaceutical composition and method for delivering a pharmaceutically active agent and sustained release method for delivering a pharmaceutically active agent
IT1303753B1 (en) * 1998-11-13 2001-02-23 Ct Lab Farm Srl administrable pharmaceutical compositions for oral contenentiun gastro-resistant coating based on acrylic polymers.
NZ513037A (en) * 1999-01-29 2003-05-30 Disphar Internat B Coated sustained release pharmaceutical composition for the release of an agent in the gastrointestinal tract
ITMI991316A1 (en) * 1999-06-14 2000-12-14 Cip Ninety Two 92 S A oral pharmaceutical compositions in modified release mesalazine
JP2001055322A (en) 1999-08-18 2001-02-27 Tanabe Seiyaku Co Ltd Pulse release type preparation
JP4439629B2 (en) * 1999-09-14 2010-03-24 久光製薬株式会社 Packaging bag
US6199698B1 (en) * 1999-12-03 2001-03-13 Alusuisse Technology & Management, Ltd. Pharmaceutical packaging with separation means
US6627223B2 (en) 2000-02-11 2003-09-30 Eurand Pharmaceuticals Ltd. Timed pulsatile drug delivery systems
IT1318376B1 (en) 2000-03-07 2003-08-25 Pharmatec Internat S R L Forms solid oral controlled-release mesalazine containing active comeprincipio.
DE10013030A1 (en) 2000-03-17 2001-09-20 Roehm Gmbh Formulation for treating ulcerative colitis, comprising active agent, e.g. 5-aminosalicylic acid or prednisone, coated with acrylic copolymer to provide delayed release at high pH in the colon
IT1318625B1 (en) * 2000-07-14 2003-08-27 Roberto Valducci solid oral pharmaceutical formulations multifasicoph-dependent release.
AU6552500A (en) * 2000-08-29 2002-03-13 Mepha Ag Medicament for treating intestinal diseases
US20020177579A1 (en) * 2000-11-06 2002-11-28 Larry Augsburger Extended release formulation of water-soluble drugs
EP1441700B1 (en) * 2001-10-15 2007-08-29 Ferring BV Method for the preparation of a pharmaceutical composition comprising 5-aminosalicyclic acid for use in treatment of ulcerative colitis and crohn's disease
US8282955B2 (en) 2001-10-15 2012-10-09 Ferring B.V. Method for the preparation of a pharmaceutical composition comprising 5-aminosalicylic acid for use in treatment of ulcerative colitis and Crohn's disease
US7025205B2 (en) * 2002-06-26 2006-04-11 Aventis Pharma Limited Method and packaging for pressurized containers
AT536930T (en) 2002-11-26 2011-12-15 Univ Gent Method and apparatus for wet granulation of powder
CA2520197A1 (en) 2003-04-23 2004-11-04 Ferring B.V. Sachet for a pharmaceutical composition
EP1547601A1 (en) 2003-12-23 2005-06-29 Ferring B.V. Coating method
JPWO2008102671A1 (en) * 2007-02-22 2010-05-27 味の素株式会社 Method of purifying 4-hydroxy isoleucine
EP2340812A1 (en) 2009-12-18 2011-07-06 Ferring International Center S.A. Granules for pharmaceutical preparations, methods and apparatus for their production

Also Published As

Publication number Publication date
NO20055534L (en) 2005-11-23
JP2006524207A (en) 2006-10-26
RU2547552C2 (en) 2015-04-10
SI1615648T1 (en) 2014-11-28
CA2520026A1 (en) 2004-11-04
US8858992B2 (en) 2014-10-14
WO2004093884A3 (en) 2005-01-27
WO2004093884A2 (en) 2004-11-04
US20150209297A1 (en) 2015-07-30
HK1198917A1 (en) 2015-06-19
CN1777430A (en) 2006-05-24
CA2520026C (en) 2010-02-23
CY1115560T1 (en) 2017-01-04
NO335375B1 (en) 2014-12-01
EP1615619A2 (en) 2006-01-18
HK1083312A1 (en) 2014-11-07
WO2004093883A2 (en) 2004-11-04
JP2010179109A (en) 2010-08-19
US20070042143A1 (en) 2007-02-22
ES2486245T3 (en) 2014-08-18
US9402815B2 (en) 2016-08-02
EP1615648B1 (en) 2014-05-07
AU2004231316B2 (en) 2008-02-21
RU2005131492A (en) 2006-04-27
JP4753864B2 (en) 2011-08-24
IL170978A (en) 2015-04-30
RU2009111609A (en) 2010-10-10
EP1615648A2 (en) 2006-01-18
WO2004093883A3 (en) 2004-12-16
JP2010090146A (en) 2010-04-22
PT1615648E (en) 2014-08-26
JP2007523664A (en) 2007-08-23
KR100849966B1 (en) 2008-08-01
DK1615648T3 (en) 2014-08-11
AU2004231316A1 (en) 2004-11-04
CN1777430B (en) 2010-06-09
EP2756844A1 (en) 2014-07-23
MXPA05011308A (en) 2005-12-12
KR20060003362A (en) 2006-01-10
US20070043004A1 (en) 2007-02-22
NZ542591A (en) 2009-02-28

Similar Documents

Publication Publication Date Title
CA2163655C (en) Packaging material comprising a water-soluble film
CA2378773C (en) Self-heating flexible package
EP0142950B1 (en) Disposable bags
JP4763590B2 (en) Modified starch and iota - carrageenan and containing a film-forming composition and method for producing soft capsules using the same
JP3166123B2 (en) Drug packaging
EP1577363A1 (en) Exothermic composition and exothermic element
EP1615648B1 (en) High drug load mesalazine sachet
RU2215656C2 (en) Packaging material for nicotine-containing product
JP4727658B2 (en) Disposable compounding device
JP6277189B2 (en) Water-soluble package comprising a bittering agent
WO2003097764A1 (en) Heating composition and heating element
EP1404269A1 (en) Wound dressings and wound treatment compositions
KR20000069809A (en) A thermal pack having a plurality of individual heat cells
US6113927A (en) Package and packaging method for aqueous liquid materials
KR100893643B1 (en) Atmosphere improving tape for package, package with atmosphere improving tape and method of manufacturing the package, package container with atmosphere improving tape, engaging device, and package with engaging device
HU225551B1 (en) Primary packaging unit for film-like or oblate-like dosing units and process for its production
JP2006334819A (en) Blister film and blister packaging container
JPH0818927B2 (en) The sustained release pheromone formulation
CN1038327A (en) Recovery of oil from oil reservoirs
JP2003533295A (en) Storage method and package of the pharmaceutical of containing pressure vessel
JP2004536748A (en) Improvements to compositions
JP2016537279A (en) Flexible container which can be easily emptied
CN107848684A (en) Flexible containers with puckered corners
CA2454432A1 (en) Water soluble packaging
US6596191B2 (en) Oxygen absorbing composition, oxygen absorbing resin composition using the oxygen absorbing composition, and preserving method utilizing these compositions

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead